Regeneron makes $80M obesity deal with Hansohnews2025-06-02T15:11:14+00:00June 2nd, 2025|Endpoints News|
Bristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drugnews2025-06-02T10:45:32+00:00June 2nd, 2025|Endpoints News|
Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciencesnews2025-05-29T23:30:43+00:00May 29th, 2025|Endpoints News|
TCG’s R&D venture team makes a T cell engager deal with Shanghai biotechnews2025-05-27T10:00:57+00:00May 27th, 2025|Endpoints News|
Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBionews2025-05-20T07:24:02+00:00May 20th, 2025|Endpoints News|
In the Future, China Will Be Dominant. The U.S. Will Be Irrelevant.news2025-05-19T06:19:57+00:00May 19th, 2025|The New York Times|
Merck KGaA Q1 earnings: Tariff surcharge for US customers will continuenews2025-05-15T11:03:52+00:00May 15th, 2025|Endpoints News|
Hengrui, one of China’s leading biotechs, anticipates $1.2B in proposed Hong Kong listingnews2025-05-15T08:52:29+00:00May 15th, 2025|Endpoints News|
Chinese Imports to US Hit 20-Year Low as Tariffs Sink Innews2025-05-06T21:34:58+00:00May 6th, 2025|The New York Times|
Early in vivo CAR-T human data emerge from biotech trials in Chinanews2025-05-05T10:00:52+00:00May 5th, 2025|Endpoints News|
